suPARnostic® TurbiLatex now CE/IVD approved for the Abbott Architect Chemical Diagnostic instruments

2020-07-13

ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the for the Abbott Architect 4000, 8000 and 16000 platform, which allows for clinical use of suPARnostic® TurbiLatex on the Abbott Architect instruments.

Läs hela meddelandet på ViroGates hemsida.

Läs mer..



Västra Hamnen Corporate Finance AB | Jungmansgatan 12 | 211 11 Malmö | 040-200 250 | info@vhcorp.se